ADMA Biologics to Participate in the Raymond James Institutional Investor Conference

Rhea-AI Summary

ADMA Biologics (Nasdaq: ADMA) has announced its participation in the upcoming Raymond James Institutional Investor Conference. The company's President and CEO, Adam Grossman, will engage in a fireside chat scheduled for March 5, 2025, at 11:35 a.m. ET.

Investors and interested parties can access the live audio webcast through the 'Events & Webcasts' section of ADMA's investor relations website at ir.admabiologics.com/events-webcasts. The archived version of the webcast will be made available approximately two hours after the event concludes.

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Raymond James Institutional Investor Conference on March 5, 2025, at 11:35 a.m. ET.

A live audio webcast of the call will be available under “Events & Webcasts” in the investor section of the Company’s website, https://ir.admabiologics.com/events-webcasts. An archived webcast will be available on the Company’s website approximately two hours after the event.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty biologics and human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

INVESTOR RELATIONS CONTACT:
Argot Partners | 212-600-1902 | ADMA@argotpartners.com

FAQ

When is ADMA Biologics presenting at the Raymond James Conference 2025?

ADMA Biologics will present on March 5, 2025, at 11:35 a.m. ET during the Raymond James Institutional Investor Conference.

How can investors watch ADMA's Raymond James Conference presentation?

Investors can watch the live audio webcast through the 'Events & Webcasts' section on ADMA's investor website at ir.admabiologics.com/events-webcasts.

Will ADMA's Raymond James Conference presentation be available after the event?

Yes, an archived version of the webcast will be available on ADMA's website approximately two hours after the event.

What type of presentation will ADMA deliver at the Raymond James Conference?

ADMA's CEO Adam Grossman will participate in a fireside chat format presentation at the conference.